Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
Yushi NaitoMasashi KatoHideji KawanishiAkiyuki YamamotoFumitoshi SakamotoHiroki HirabayashiMasataka KobayashiYoshihisa MatsukawaTohru KimuraHidemori ArakiToshinori NishikimiAtsuya KondoYasushi YoshinoYoshimasa HashimotoYojiro NakanoToyonori TsuzukiPublished in: The Prostate (2022)
The findings highlight a high prevalence of IDC-P among patients with mHSPC and suggest that IDC-P positivity may be a reliable indicator that ARAT should be implemented as first-line treatment.